Research and Markets: Kidney Cancer Global Clinical Trials Review, Q4, 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/6fa36a/kidney_cancer_glob) has announced the addition of GlobalData's new report "Kidney Cancer Global Clinical Trials Review, Q4, 2010" to their offering.

"Kidney Cancer Global Clinical Trials Review, Q4, 2010" provides data on the Kidney Cancer clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Kidney Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating Kidney Cancer.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope

  • Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status and trial success rate
  • Review of key discontinued trials (suspended, withdrawn and terminated)
  • Overview of the enrollment pattern by phase for the past decade
  • Number of clinical trials segmented by key drugs
  • Clinical trial overview of top 20 companies, which include Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, and so on.
  • Clinical trial overview of top 20 Universities / Institutes / Hospitals including National Cancer Institute, Cancer Research UK, Cancer Research Institute, and others

Key Topics Covered:

  • List of Tables
  • List of Figures
  • Introduction
  • Kidney Cancer
  • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by BRIC Nations
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Unaccomplished Trials of Kidney Cancer
  • Subjects Recruited Over a Period of Time
  • Prominent Sponsors
  • Top Companies Participating in Kidney Cancer Therapeutics Clinical Trials

For more information visit http://www.researchandmarkets.com/research/6fa36a/kidney_cancer_glob



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Clinical Trials  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.